Introduction
The role of the serum bactericidal test (SBT) in the management of clinical infection remains controversial despite debate about its role for at least the last 15 years. The value of the SBT in the management of infective endocarditis has been questioned, [1] [2] [3] but others continue to recommend its use. [4] [5] [6] In contrast to infective endocarditis, other indications for the test appear now to include acute or chronic osteomyelitis 7 or cystic fibrosis. 8 In addition it has been suggested for many years that serum bactericidal activity is a useful method for monitoring antimicrobial therapy in Gram-negative bacteraemia. Performance in the first distribution was acceptable for 75% of laboratories but in the second only 34% could identify penicillin tolerance; 34 respondents reported an SBT result of 2 for the tolerant strain, 81 laboratories reported one of 16. Technical factors related to acceptable performance were: sonication of broth before counting the inoculum; knowing the inoculum size in cfu/mL; use of a 4-8 h broth culture to make the inoculum; incubation of recovery plates for >36 h; use of a calibrated pipette to sample for surviving bacteria; use of measured volumes to add the inoculum. Use of uncalibrated pipettes or standard loops to recover survivors was related to poor performance. Microbiology departments in the UK should review the clinical need to perform the SBT in the light of their local circumstances and if they elect to continue to offer this test, revise their methodologies which could be producing misleading results when testing -haemolytic streptococci.
during the management of infective endocarditis, a wide variety of techniques, endpoints and interpretative criteria being used. Since that time further guidance on the technical aspects of performing the test have been published. 11, 12 It was our impression, however, that although many laboratories in the UK perform SBTs, many different methods remain in use and there is no external quality assessment (EQA). The objectives of this study were: to assess the number of UK laboratories that perform SBT in the UK; to determine the reasons why this test is used, the value placed on the results by microbiologists and the interpretative criteria used; to determine the many technical variables in the test and their association with ability to repeat a pre-determined result. To this end we conducted two experimental EQA circulations with three bacterial isolates and two sera supported by a written questionnaire on methodology and interpretation. . The results of these laboratories were used in setting the target result range which was to be considered as acceptable performance. Returns from all participants were entered into a database (Access 2, Microsoft Corporation, USA). The factors associated with good or bad laboratory performance were determined by simple univariate analysis.
Methods

Participants in the UK
To identify technical factors positively or negatively associated with acceptable performance, groups were selected on the basis of individual technical features. The percentage acceptable performance in each group was compared with the overall percentage acceptable performance for each of the three strains. When a group contained at least 15 laboratories and the level of acceptable performance was 10% above or below the overall level then it was considered that the particular technical feature showed a positive or negative association with acceptable performance. The statistical significance of any association was tested using a chi-squared test. 13 A value of P 0.05 was taken as the level of statistical significance; however, some features where P was 0.1 but 0.05 were included since it was considered that these features might be of importance with regard to performance even though statistical significance was not obtained due to the small numbers involved.
S. sanguis PAJ 107/4184 was penicillin-tolerant and, to make it easier to identify factors associated with the detection of penicillin tolerance, some returns were excluded. These were borderline results with the tolerant strain (bactericidal titre 8 or 16) and a small number (n 6) of presumed blunders such as result transpositions (wrong strain found tolerant), and results where both the bacteriostatic and bactericidal titres for the tolerant strain were 4 (little or no antimicrobial activity).
Results
Non-technical questionnaire
Laboratories were asked about the numbers of SBTs performed each year, the clinical circumstances in which they were performed, the value they placed on the results and the interpretative criteria used. One hundred and thirtytwo respondents (66%) performed 10 tests per annum while 9% (n 18) did 20 tests and 3% (n 6) did 40 tests per annum. More than a third (36%, n 72) did 5 tests in a year.
The (n 6). Despite being recommended by many respondents in the management of infective endocarditis only 25.2% (n 48) often or always changed therapy on the basis of results (Table I) . A lower percentage often or always changed therapy on the basis of the tests for immunocompromised patients 12.3% (n 6), osteomyelitis 13.6% (n 1 1 ) or acute meningitis 14.3% (n 8), but over 100 laboratories did not do tests in these conditions (Table I) . For infective endocarditis and the other conditions listed in Table I most respondents sometimes changed therapy on the basis of the test. When asked whether they believed the bactericidal test was useless, occasionally useful, often useful or always useful, 3% (n 6) regarded the test as useless; 55.6% (n 110) regarded it as occasionally useful, 30.8% (n 61) regarded it as often useful and 10.6% (n 21) as always useful.
There was considerable variability in the interpretation of SBT results. Respondents were asked to state the results they would regard as a satisfactory titre for infective endocarditis due to -haemolytic streptococci and Enterococcus spp. and gave 78 different combinations of answers. The results for those recommendations supported by at least five laboratories are listed in Table  II . Most laboratories regard both isolates as being equivalent with regard to a satisfactory titre with a pre-dose titre of 8, with a post-dose titre of 32 being recommended by 26 laboratories; 20 departments also recommended a pre-dose titre of 4 with a post-dose titre of 8 or a pre-dose titre of 4 and post-dose titre of 16.
First experimental EQA distribution
In the first distribution, S. aureus NCTC 6571 was t e s t e d against serum spiked with vancomycin 38 mg/L plus gentamicin 0.5 mg/L. Two hundred laboratories returned a result and these ranged from 2 to 512. Repeated testing of the serum and S. aureus by the 'expert' laboratories indicated a bactericidal titre of 8 or 16 hence any result between 4 and 32 inclusive was considered acceptable performance (Table III) . Seventy-five per cent (150/200) of laboratories returned a result in this range (Figure) . A summary of the results of the technical questionnaire and its relation to acceptable performance is shown in Table  IV . If factors which deviate from the overall level of performance by 10% and for which 15 laboratories responded are listed, then only the use of Mueller-Hinton broth (85.7% acceptable) and a plate culture to make the inoculum (89.3% acceptable) were associated with acceptable performance while the use of brain heart infusion broth (61.5% acceptable) was associated with poor performance.
In addition to a wide variety of different techniques, the definition of 'kill' used in the bactericidal test was varied. Ten respondents defined kill as a 90% reduction, 46 as a 99% reduction, 98 as a 99.9% reduction and 28 as a 99.99% reduction in cfu/mL. Fourteen respondents used other criteria. When the data for the first circulation were analysed using 2 no technical factors were significantly associated with poor or acceptable performance (P 0.05).
Second experimental EQA distribution
The second circulation consisted of two strains of -haemolytic streptococci, one of which was penicillintolerant. The results of the expert laboratories, target results and percentage of acceptable performance are shown in Table III MBC 128 mg/L) ranged from 2 to 1024 with a bimodal distribution. The most common return was 2 (n 25) followed by 64 (n 21) and 128 (n 20) (Figure) . When borderline results (bactericidal titre 8 or 16) and possible blunders were excluded the number of returns available for analysis was 117, of which only 34.2% (n 40) produced an acceptable performance-i.e., found the penicillin-tolerant S. sanguis to have a low bactericidal titre and a high bacteriostatic titre and the non-tolerant strain to have a high titre. One hundred and twenty-six laboratories returned a titre of 16 (96%) for the S. oralis and only 1.5% (n 2) a titre of 2. Using S. sanguis 62% (81/130) returned a titre of 16 and 26% (34/130) a titre of 2 ( Figure) . Table V compares the results of various methodological factors with outcome. Factors that resulted in a higher proportion of acceptable performance, that is 10% above the overall level, were use of Mueller-Hinton broth (47.1% acceptable); a 4-8 h broth culture for the inoculum (68.8% acceptable); a measured volume to add to the inoculum (46.8% acceptable); an inoculum of 1-9 10 5 cfu/mL (48.8% acceptable); a calibrated pipette to recover survivors (51.6% acceptable) and the addition of -lactamase to the recovery medium (53.3% acceptable). The use of an inoculum of 1 10 5 cfu/mL was associated with a high proportion of poor performance (only 16.7% acceptable) and laboratories not determining the size of the inoculum did uniformly badly (no acceptable performers). When the data were analysed using 2 , several factors emerged as being important to acceptable and poor outcome. Factors significantly associated (P 0.05) with acceptable or poor performance and those which may be associated with acceptable or poor performance (P 0.1) are given in Table VI . Again factors related to counting bacteria feature strongly such as sonication before counting the inoculum, knowing the size of the inoculum, use of calibrated pipettes and use of measured volumes. Use of an inoculum of 1-9 10 5 cfu/mL and prolonged incubation of recovery plates also appeared to have an effect.
Discussion
A large number of laboratories in the UK still perform the SBT; 200 took part in our first circulation and 137 in the second. Most laboratories continue to use it in infective endocarditis though fewer perform the test on all patients with a significant isolate than in the previous review of practice in the UK by Eykyn 3 (61% of patients with significant isolates in 1994 compared with 77.9% in the mid-1980s). However, 87.3% of respondents still perform the test in the vast majority of patients with infective endocarditis. This strong adherence to the SBT may be related to the recommendations of the Infective Endocarditis Working Party of the British Society of Antimicrobial Chemotherapy.
14 Confidence in the results of the test is, however, in decline. Previously 85% (73/84) would alter the antimicrobial regimen if the result was unsatisfactory titre while now only 25% often or always change therapy on the basis of results. As before there was considerable variation in the endpoints used to define bactericidality as well as the interpretative criteria used. 3 Continued variation in methodology is perhaps surprising in view of the large body of recently published data on how methodology affects determination of the SBT, 12, 15 but confusion related to the interpretative criteria for the SBT in infective endocarditis reflects the wide range of criteria suggested. 6, 4, 14 Uniform interpretative criteria are difficult to lay down in circumstances in which the technical variables in performing the test vary widely. The technical factors related to acceptable or poor performance in these two EQA distributions can be summarized (Table VI) . Most factors relate to counting bacterial numbers, for example knowing the size of the inoculum, sonication of -haemolytic streptococci before counting, use of calibrated pipettes or measured serum or broth volumes. The inoculum itself was an important factor as has been described before 12 and the use of incubation of recovery plates for 36 h and addition of -lactamase may also help. Furthermore the use of log-phase rather than lag-phase inocula may be of value but the evidence from these EQA distributions is not entirely clear. The use of Mueller-Hinton broth may be related to acceptable performance and the use of brain heart infusion broth to poor performance. The NCCLS 12 has recommended the use of Mueller-Hinton broth and laboratories using the NCCLS method may also be those paying close attention to bacterial counting. Despite these variations in performance of the test, most (75%) laboratories achieved acceptable performance with S. aureus. In contrast, only 35% could differentiate penicillin-tolerant and non-tolerant -haemolytic streptococci on serum bactericidal testing. Therefore when S. sanguis PAJ 107/4184 (penicillin MBC 128 mg/L) was tested with sera containing 15 mg/L of penicillin only 37 respondents reported a serum bactericidal titre of 2 while 81 reported a result of 16. These results combined with the questionnaire results indicating poor adherence to basic bacterial counting techniques lead us to question the technical validity of the results of SBTs performed in many laboratories in the UK for -haemolytic streptococci.
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In conclusion, while many laboratories perform the SBT a declining number are confident in the clinical value of the results they produce in the context of managing patients with infective endocarditis. These experimental EQA distributions have indicated that for S. aureus serum bactericidal testing is more satisfactory than forhaemolytic streptococci. Indeed most laboratories produced serum bactericidal testing results which were highly misleading with the penicillin-tolerant S. sanguis. It now seems an opportune moment for laboratories to review the clinical need for them to perform SBTs at all and, if they decide to continue, to revise their methodologies in order to pay particular attention to bacterial counting, inoculum size, definitions of bactericidality, phase of bacterial growth and how survivors are to be recovered. There is much room for improved clarity on the role of the SBT in managing infection which may be a difficult objective to achieve, while the technical quality of testing could be more easily improved. use of an overnight broth to make the inoculum 3.89 use of brain heart infusion broth 3.67 Factors which may be related to acceptable performance in the QA circulation with -haemolytic streptococci (P 0.1):
use of an inoculum of 1-9 10 5 cfu/mL 3.09 addition of -lactamase to the recovery medium 2.85
